接受平衡晶体液或0.9%氯化钠静脉输液治疗的成人血清氯浓度与结局
该研究是对一项随机对照试验的二次分析,根据基线血清氯浓度和pH的四分位数将患者分组,主要终点为90天死亡率。共纳入4823例有相关基线数据的患者,氯浓度四分位组分别为<102、102-106、107-109和>109 mmol/L。从最低到最高氯浓度亚组,平衡液相比生理盐水的风险校正90天死亡比值比分别为1.23(0.95-1.58)、0.95(0.73-1.25)、0.88(0.64-1.21)和0.76(0.57-1.01),交互作用P=0.10;pH四分位组的交互作用P=0.63。结论认为,根据基线血清氯浓度或pH,平衡液相比生理盐水的治疗效果无显著差异。
要点
- 在4846例有结局数据的患者中,4823例有相关基线数据被纳入分析,氯浓度四分位组例数分别为1347、1333、993和1150例。
- 从最低到最高氯浓度亚组,平衡液相比生理盐水的风险校正90天死亡比值比分别为1.23(0.95-1.58)、0.95(0.73-1.25)、0.88(0.64-1.21)和0.76(0.57-1.01),交互作用P=0.10。
- 从最低到最高pH四分位组,平衡液相比生理盐水的风险校正90天死亡比值比分别为0.89(0.69-1.15)、0.94(0.70-1.27)、0.96(0.67-1.38)和1.15(0.82-1.60),交互作用P=0.63。
- 结论认为,根据基线血清氯浓度或pH,平衡液相比生理盐水的治疗效果无显著差异。
适用人群与场景
- ICU接受静脉液体治疗(平衡晶体液或0.9%氯化钠)的成人患者,且有基线血清氯浓度和pH数据。
诊断标准与关键阈值
- 基线血清氯浓度四分位分组:<102、102-106、107-109、>109 mmol/L。
- 基线pH四分位分组:≤7.27、7.27-7.34、7.34-7.39、>7.39。
研究设计与关键结果
- 研究类型:一项随机对照试验的二次分析。
- 样本量:4846例有结局数据,4823例有相关基线数据纳入分析。
- 氯浓度四分位组例数:<102 mmol/L组1347例,102-106 mmol/L组1333例,107-109 mmol/L组993例,>109 mmol/L组1150例。
- 主要终点:90天死亡率。
- 从最低到最高氯浓度亚组,平衡液相比生理盐水的风险校正90天死亡比值比分别为1.23(95%CI 0.95-1.58)、0.95(0.73-1.25)、0.88(0.64-1.21)和0.76(0.57-1.01),交互作用P=0.10。
- 从最低到最高pH四分位组,平衡液相比生理盐水的风险校正90天死亡比值比分别为0.89(95%CI 0.69-1.15)、0.94(0.70-1.27)、0.96(0.67-1.38)和1.15(0.82-1.60),交互作用P=0.63。
证据类型、等级与局限
- 证据类型:随机对照试验的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论认为,根据基线血清氯浓度或pH,平衡液相比生理盐水的治疗效果无显著差异;原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To determine whether there is an interaction between baseline serum chloride concentration and pH and treatment effects in Intensive Care Unit (ICU) patients receiving intravenous fluid therapy with balanced solution versus 0.9% sodium chloride (saline).
METHODS: A secondary analysis of a randomized controlled trial in which patients were divided into cohorts according to quartiles of baseline serum chloride concentration and pH. The primary outcome was day-90 mortality.
RESULTS: From 4846 patients with outcome data available, 4823 with relevant baseline data were included in this analysis, with 1347, 1333, 993 and 1150 patients in the chloride quartiles of < 102, 102-106, 107-109 and > 109 mmol/L, respectively. Data were also analysed in pH quartiles of ≤ 7.27, 7.27-7.34, 7.34-7.39 and > 7.39. The risk-adjusted odds ratio (95% confidence interval [CI]) for day-90 mortality for patients assigned balanced solution compared to saline was 1.23 (0.95-1.58), 0.95 (0.73-1.25), 0.88 (0.64-1.21), and 0.76 (0.57-1.01) for lowest to highest chloride subgroups, respectively (P value for interaction = 0.10), and 0.89 (95% CI 0.69-1.15), 0.94 (0.70-1.27), 0.96 (0.67-1.38) and 1.15 (0.82-1.60) for pH quartiles from lowest to highest, respectively (P value for interaction = 0.63).
CONCLUSIONS: There were no significant differences in the treatment effect of balanced solutions compared to saline according to baseline serum chloride concentration or pH.
参考来源
- Ramanan M, Hammond N, Billot L, et al. Serum chloride concentration and outcomes in adults receiving intravenous fluid therapy with a balanced crystalloid solution or 0.9% sodium chloride. Intensive Care Med. 2025. PMID: 39928118. doi:10.1007/s00134-024-07764-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。